

Alaska Medicaid Pharmacy and Therapeutics Committee

Meeting date April 19, 2013

Frontier Building, 3601 C Street; Room 890/896

Agenda

Call in: 1-800-315-6338. Use access code 735#.

1. **Call to Order – Chair** **8:00 am**
2. **Roll Call** **8:05 am**
3. **Public Comment - Local Public / Health Practitioners**

The Department's method for class review are to better utilize the time of the P&T Committee. Classes shown in **Red** are new classes or classes where ****new information exists and public testimony will be taken.** Public testimony will be taken for classes shown in **Blue** will only if ****new information is received.** Classes shown in **Green**, no significant changes have been noted and no public testimony will be taken.

****New information includes: new indications or drugs, new warnings, or new head to head clinical evidence.**

4. Public comment , discussion & vote on **Red Classes**

Tab 1 - Re-review Antibiotics - Gastrointestinal	Tab 2 - Re-review Beta ₂ Adrenergic Agents – Long Acting
--	---

5. Public comment, discussion & vote **Blue Classes**

Tab 3 - Re-review Intranasal Rhinitis Agents	Tab 4 - Re-review Otic Antibiotics (previously reviewed as “Otic Quinolones”)
Tab 5 - Re-review Antiemetics/Antivertigo Agents (previously reviewed as “Anti-Emetics”)	Tab 6 - Re-review Glucocorticoids, Inhaled (previously reviewed as “Inhaled Steroids”)
Tab 7 - Re-review Ophthalmic Antibiotics (previously reviewed as “Ophthalmic Quinolones” and “Ophthalmic Macrolides”)	Tab 8 - Re-review Cephalosporins and Related Antibiotics (previously reviewed as “2 nd and 3 rd Generation Cephalosporins”)

6. Discussion & vote on **Green Classes**

Tab 9 - Re-review Hepatitis C Agents	Tab 10 – Re review – Antifungals – Onychomycosis
Tab 11 - Re-review Ophthalmics for Allergic Conjunctivitis (previously reviewed as “Ophthalmic Anti-Allergy Agents” and “Ophthalmic Mast Cell Stabilizers”)	Tab 12 - Re-review Antimigraine Agents
Tab 13 - Re-review Ophthalmic Cyclosporine Emulsion (previously reviewed as “Ophthalmic Immunomodulator”)	Tab 14 - Re-review Leukotriene Modifiers
Tab 15 - Re-review Beta ₂ Adrenergic Agents – Short Acting	Tab 16 - Re-review Low-Sedating Antihistamines
Tab 17 - Re-review COPD Agents (previously reviewed as “COPD Inhalant Drugs”)	Tab 18 - Re-review Tetracyclines
Tab 19 - Re-review Fluoroquinolones (previously reviewed as “2 nd and 3 rd Generation Quinolones”)	Tab 20 - Re-review Macrolides - Ketolides
Tab 21 - Re-review Antivirals, Herpes Simplex Virus (previously reviewed as “Antivirals, Oral”)	Tab 22 - Re-review Antiviral Agents, Topical
Tab 23 - Re-review Ophthalmic Anti-Inflammatories	Tab 24 - Re-review Topical Antifungals
Tab 25 - Re-review Hepatitis B Agents	Tab 26 - Re-review Ophthalmic Antibiotic-Steroid Agents
Tab 27 - Re-review Antivirals, Influenza	

7. **Break as needed** – 15 minutes
8. **Review minutes** from **November 16, 2012 meeting and January 18, 2013 meeting**
9. **Election of new Chair and vice-chair.**
10. **Comments from Committee Members or Chair**
11. **Adjourn**

Next Meeting Date: TBD